EU approval in sight for Oxford gene company

Oxford Biomedica said the EU committee that evaluates drugs and advises the European Medicines Agency had “adopted a positive opinion” on recommending the Kymriah drug for the treatment of two blood cancers. Part of the drug is made by Oxford Biomedica. Kymriah uses a patient’s own cells to fight cancer.